The Engine has co-led by $16m seed round for Cellino, which is working on a process to automate the generation of stem cells at scale.

CAS Investment Management, a subsidiary of Chinese Academy of Sciences, has backed medical devices developer Resproly’s series B round.

Mental healthcare services provider Alma pushed its overall funding past the $40m mark with a series A round that included Optum Ventures.

Bertelsmann Asia Investments contributed to a series A round that will fund preclinical development of NeoX's immuno-oncology drug pipeline.

Chishima Real Estate, M3, Miraca, Nippon Life, POC Clinical Research, Reprocell, Toho Holdings and Zenoaq have all scored exits after the cell therapy provider went public.

The venture capital firm is teaming up with Illumina on a genomics incubator and with China Pacific Insurance on a medical technology fund.

Q&A with Anil Achyuta, investment director, TDK Ventures

The Xiamen C&D-backed generic drug developer has pulled in new funding ahead of plans to list on a China-based stock exchange.

The GV-backed stem cell drug developer has set terms for an initial public offering that would raise between $300m and $345m.

Volpara Health has acquired CRA Health, a spinout of Havard Medical School’s teaching hospital Massachusetts General Hospital.